SAN DIEGO, CA / ACCESSWIRE / April 7, 2020 / Nascent Biotech, Inc. (NBIO), today announced that two independent consultants retained by the Company have begun preliminary research on a possible treatment for patients infected with the Coronavirus. An article in The Journal of Biological Medicine (Yu et al. Journal of Biomedical Science (2016) 23:14 DOI 10.1186/s12929-016-0234-7) specifically mentioned cell surface vimentin as a potential target in the treatment of conditions related to the Coronavirus.
Nascent founder and Advisory Board Chairman, Dr. Mark Glassy, commented that, "Our third party consultants have begun testing the ability of Pritumumab to interfere with the virus' binding to its target cells, thus ameliorating - and possibly eliminating - the potential deadly effects. Nascent is committed to changing patient expectations in this debilitating disease and exploring Pritumumab's ability to fight Covid-19, further optimizing this promising drug's potential."
Nascent Biotech, Inc is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers. Its products are not commercially available.
Statements in this press release about our future expectations constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc's ability to target the medical professionals; Nascent Biotech Inc's ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc's Form 10, filed on May 2, 2015, and future subsequent filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
ICS, an Endicott-headquartered technology management services company, acquired Brightworks Computer Consulting, a firm based in Ithaca, on March 10.
Sixteen Brightworks employees are joining ICS, which already has an office in Cayuga Heights, however they will continue to work from their office on State Street in Ithaca.
“Due to the ever-changing information technology landscape and the growing cybersecurity needs, we wanted to find a partner that could support our customers with a higher level of maturity and serviceability than we could achieve in the near future," said Brightworks founder John Guttridge in a statement.
Guttridge is continuing to manage clients as a senior account manager for ICS. Guttridge, who is also a developer for Urban Core LLC, continues to be the landlord for the Ithaca Journal building, which will serve as the Ithaca location for ICS at 123 West State St.
ICS started as a three-person information technology business in 2005 in Endicott and has since grown to a company employing 90 people in offices in Endicott, Syracuse and Tompkins County.
- When all the firms are engaging employees on a large-scale of number, it becomes virtually impossible for a human eye to monitor the work-efficiency of each person deployed onto the field. These mobile-based applications track their progress in real-time, making it easier for the office management to record and appraise their work and allocate the right resources to them as and when is needed according to the current requirements on the field.